{
    "Question": "Should patients with MTX-naïve and non-MTX csDMARDs naïve RA and moderate to high disease activity receive csDMARD monotherapy or combination (double or triple) therapy?",
    "Comparison": 
    {
        "csDMARD double combination therapy vs csDMARD monotherapy.": 
            {
                "filename": "PICO 4a_Comparison 1.json",
                "Explanations": 
                    {
                        "a": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment in both studies, high risk of attrition bias in one of the two studies.",
                        "b": "csDMARD double therapy includes: MTZ+SSZ",
                        "c": "csDMARD monotherapy includes: MTX or SSZ",
                        "d": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment.",
                        "e": "Downgraded by one level due to serious imprecision. Low sample size.",
                        "f": "Downgraded by two levels due to very serious imprecision. Confidence intervals include both values suggesting benefit and values suggesting harm. Small sample size, very low number of events."
                      }
            },
        "csDMARD triple combination therapy vs csDMARD monotherapy. ": 
            {
                "filename": "PICO 4a_Comparison 2.json",
                "Explanations": 
                {
                    "a": "Downgraded by one level due to serious imprecision. Small sample size.",
                    "b": "csDMARD triple therapy includes: MTX+SSZ+HCQ",
                    "c": "csDMARD monotherapy includes: MTX",
                    "d": "Downgraded by one level due to serious imprecision. Confidence interval includes both values of no effect and benefit. Small sample size.",
                    "e": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Small sample size."
            }
            }
    },
    "References": 
    {
        "1": "Dougados M. Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Annals of the Rheumatic Diseases. 1999;58(4):220.",
        "2": "Haagsma C, van Riel P, de Jong A, van de Putte L. Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial. British Journal of Rheumatology. 1997;36(10):1082.",
        "3": "de Jong PHP. Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: First results of the tREACH trial. Annals of the Rheumatic Diseases. 2013;72(1):72.",
        "4": "de Jong PHP, Hazes JM, Buisman LR, Barendregt PJ, van Zeben D, van der Lubbe PA, et al. Best cost-effectiveness and worker productivity with initial triple DMARD therapy compared with methotrexate monotherapy in early rheumatoid arthritis: cost-utility analysis of the tREACH trial. Rheumatology. 2016;55(12):2138."
    }
}